Key points
- FDA 510(k) clearance received for CT-based BMD technology
- Establishes regulatory foundation for future BMD applications
- Plans to extend technology to HiRise platform for broader BMD measurement
Full summary
CurveBeam AI Limited has announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its CT-based Bone Mineral Density (BMD) technology using multidetector CT (MDCT) supine (lying-down) scans. This clearance represents an important regulatory milestone in CurveBeam AI's strategy to expand its advanced CT imaging capabilities into quantitative bone-health assessment. The clearance establishes a regulatory foundation for the company to pursue FDA clearance to extend the technology to BMD measurement on the HiRise platform, designed to provide weight-bearing CT imaging of the lower extremity. This advancement could streamline the orthopaedic imaging and surgical planning workflow, potentially integrating BMD assessment into existing CT imaging pathways.
Outlook
CurveBeam AI plans to progress regulatory planning for a CT BMD 510(k) submission for HiRise, including assessment of the appropriate regulatory pathway, clinical evidence requirements and validation activities.